CSL Ltd. — Capital/Financing Update 2022

Apr 20, 2022

For immediate release

21 April 2022

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

CSL Successfully Prices Issuance in the 144A / Reg S Market

CSL Limited (ASX:CSL; USOTC:CSLLY) announces that it has priced US$4b in the 144A / Reg S Market.

The notes have been issued by CSL Finance Plc and guaranteed by the parent company. The principal amount, tenor and coupon for each tranche of notes are as follows:

• US$500m 5-year at a fixed coupon of 3.85%

• US$500m 7-year at a fixed coupon of 4.05%

• US$1,000m 10-year at a fixed coupon of 4.25%

• US$500m 20-year at a fixed coupon of 4.625%

• US$1,000m 30-year at a fixed coupon of 4.75%

• US$500m 40-year at a fixed coupon of 4.95%

CSL intends to use the cash proceeds from the offering to partially finance the proposed acquisition of Vifor Pharma Limited announced on 14 December 2021, and for general corporate purposes.

CSL’s Chief Financial Officer, Joy Linton said “We are pleased with the outcome of the bond issue from both a demand and pricing perspective. It also provides depth and flexibility for our long-term capital management program.

“The strong support shown by investors towards our inaugural US dollar bond issue reflects positively on our track record of disciplined financial management, as well as confidence in our strategy to invest in our leading therapeutic capabilities and generate sustainable growth.”

CSL further advises that the regulatory approval process for the acquisition of Vifor Pharma Limited is on track to be completed by June 2022, as previously advised.

Settlement of the notes is expected to occur on 27 April 2022, subject to customary closing conditions.

==> picture [99 x 7] intentionally omitted <==

280171488v.2

Page 2

21 April 2022

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Disclaimer

This announcement is not an offer of securities. The securities referred to in this announcement have not been, and will not be, registered under the United States Securities Act of 1933 (the “US Securities Act”) or under the securities laws of any State or other jurisdiction of the US and may not be offered or sold in the US or to, or the benefit or account of, “US persons” (as defined in Regulation S under the US Securities Act) without registration unless in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US State securities laws.

This announcement includes “forward looking statements” within the meaning of the United States Securities Exchange Act of 1934. Forward looking statements inherently involve known and unknown risks and uncertainties. CSL provides no assurance that the forward looking statements contained herein will prove accurate. No undue reliance should be placed on any forward looking statements.

Authorised by Fiona Mead Company Secretary

FURTHER INFORMATION

For further information, please contact:

Investors: Media: Mark Dehring Jimmy Baker Head of Investor Relations Communications, Asia Pacific CSL Limited CSL Limited Telephone: +613 9389 3407 Mobile +61 450 909 211 Email: mark.dehring@csl.com.au Email: jimmy.baker@csl.com.au

==> picture [99 x 7] intentionally omitted <==

280171488v.2